Trial Profile

Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dihydroartemisinin/piperaquine (Primary)
Indications Malaria
Focus Adverse reactions; Pharmacokinetics
Acronyms ECG-Lihir

Most Recent Events

06 Jul 2022 Results published in the Antimicrobial Agents and Chemotherapy
02 Mar 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
19 Nov 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com